Helicobacter pylori infection and gastroesophageal reflux in a population-based study (the HUNT study)

Helicobacter

Volumn 12, Issue 1, 2007, Pages 16-22

  Nordenstedt, Helena ^a   Nilsson, Magnus ^a   Johnsen, Roar ^b   Lagergren, Jesper ^a   Hveem, Kristian ^b,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^c HUNT Research Centre   (Norway)

Author keywords

cagA; Gastric atrophy; Gastroesophageal reflux; Helicobacter pylori; Population based

Indexed keywords

BACTERIAL PROTEIN; CAGA PROTEIN; PEPSINOGEN I; VIRULENCE FACTOR;

ADULT; AGED; ARTICLE; BACTERIAL VIRULENCE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; NORWAY; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; SEROLOGY; STOMACH MUSCLE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ATROPHY; BACTERIAL PROTEINS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NORWAY; PEPSINOGEN A; QUESTIONNAIRES; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES;

HELICOBACTER PYLORI;

EID: 33846331235     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2007.00466.x     Document Type: Article

References (37)

1. Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-56.
2. Nilsson M, Johnsen R, Ye W, et al. Prevalence of gastro-oesophageal reflux symptoms and the influence of age and sex. Scand J Gastroenterol 2004;39:1040-5.
3. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998;43:327-33.
4. Henke CJ, Levin TR, Henning JM, et al. Work loss costs due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization. Am J Gastroenterol 2000;95:788-92.
5. Agreus L, Borgquist L. The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden. Pharmacoeconomics 2002;20:347-55.
6. Ofman JJ. The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol 2003;98 (Suppl. 3):S8-14.
7. Lagergren J, Bergstrom R, Lindgren A, et al. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
8. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
9. Banatvala N, Mayo K, Megraud F, et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
10. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001;49:330-4.
11. Wu JC, Sung JJ, Ng EK, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 1999;94:1790-4.
12. Loffeld RJ, Werdmuller BF, Kuster JG, et al. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000;62:95-9.
13. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
14. El-Serag HB, Sonnenberg A, Jamal MM, et al. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181-5.
15. Sande N, Nikulin M, Nilsson I, et al. Increased risk of developing atrophic gastritis in patients infected with CagA+ Helicobacter pylori. Scand J Gastroenterol 2001;36:928-33.
16. Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
17. Newton M, Bryan R, Burnham WR, et al. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997;40:9-13.
18. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66-72.
19. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999;94:1434-42.
20. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-8.
21. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-7.
22. Monteiro L, de Mascarel A, Sarrasqueta AM, et al. Diagnosis of Helicobacter pylori infection: noninvasive methods compared to invasive methods and evaluation of two new tests. Am J Gastroenterol 2001;96:353-8.
23. Monteiro L, Bergey B, Gras N, et al. Evaluation of the performance of the Helico Blot 2.1 as a tool to investigate the virulence properties of Helicobacter pylori. Clin Microbiol Infect 2002;8:676-9.
24. Pasechnikov VD, Chukov SZ, Kotelevets SM, et al. Invasive and non-invasive diagnosis of Helicobacter pylori-associated atrophic gastritis: a comparative study. Scand J Gastroenterol 2005;40:297-301.
25. Hallissey MT, Dunn JA, Fielding JW. Evaluation of pepsinogen A and gastrin-17 as markers of gastric cancer and high-risk pathologic conditions. Scand J Gastroenterol 1994;29:1129-34.
26. Johnsen R, Bernersen B, Straume B, et al. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. BMJ 1991;302:749-52.
27. Di Mario F, Ingegnoli A, Altavilla N, et al. Influence of antisecretory treatment with proton pump inhibitors on serum pepsinogen I levels. Fundam Clin Pharmacol 2005;19:497-501.
28. Tsai SH, Chen CM, Chang CS, et al. Effect of Helicobacter pylori infection on intragastric acidity in patients with reflux esophagitis. J Gastroenterol 2004;39:821-6.
29. Mihara M, Haruma K, Kamada T, et al. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis. Gut 1996;39 (Suppl. 2):A94.
30. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pylori infection and gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2003;18:279-89.
31. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002;37:785-91.
32. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997;41:277-80.
33. Wu JC, Chan FK, Ching JY, et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004;53:174-9.
34. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42. [Erratum, Lancet 2001; 358: 1734.].
35. Raghunath AS, Hungin AP, Wooff D, et al. Systematic review: the effect of Helicobacter pylori and its eradication on gastro-oesophageal reflux disease in patients with duodenal ulcers or reflux oesophagitis. Aliment Pharmacol Ther 2004;20:733-44.
36. Moayyedi P, Bardhan C, Young L, et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001;121:1120-6.
37. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004;53:12-20.